![]() |
市場調查報告書
商品編碼
1951151
高解析度熔融分析市場-全球產業規模、佔有率、趨勢、機會與預測:產品與服務、應用、終端用戶、地區與競爭格局,2021-2031年High-Resolution Melting Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Service, By Application, By End User, By Region & Competition, 2021-2031F |
||||||
全球高解析度熔融分析市場預計將從 2025 年的 25.9 億美元成長到 2031 年的 45.4 億美元,複合年成長率為 9.81%。
高解析度熔解曲線分析是一種專門用於檢測核酸序列中基因突變的技術,其原理是透過觀察雙鏈DNA結合染料在熱變性過程中的螢光變化。與定序相比,此方法速度更快、成本更低,因此市場成長主要得益於其速度優勢,使其成為大規模基因分型和甲基化研究的理想選擇。此外,感染疾病和遺傳性疾病的日益增加也推動了這類便利診斷工具的需求。根據歐洲醫療技術協會(MedTech Europe)2024年發布的報告,歐洲醫療技術產業的價值約為1,700億歐元,其中體外診斷是主要驅動力,凸顯了支撐這些分析方法的強大產業生態系統。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 25.9億美元 |
| 市場規模:2031年 | 45.4億美元 |
| 複合年成長率:2026-2031年 | 9.81% |
| 成長最快的細分市場 | 試劑和耗材 |
| 最大的市場 | 北美洲 |
然而,由於成本下降和次世代定序技術的廣泛應用,市場面臨巨大的障礙。這些競爭技術在識別罕見變異方面具有更高的靈敏度和多重分析能力,在複雜的臨床場景中,其解析度往往優於熔解曲線分析。因此,需要進行全面基因組分析的實驗室擴大選擇定序平台而非熔解曲線分析,這一趨勢可能會限制熔解曲線分析在高階診斷領域的應用。
感染疾病和遺傳疾病的日益增多是全球高解析度熔解曲線分析市場的主要驅動力,催生了對快速且經濟實惠的突變掃描能力的需求。日益成長的健康負擔促使臨床檢查室採用熔解曲線分析技術,該技術繞過了定序的複雜性,能夠有效地識別病原體和單核苷酸多態性(SNP)。例如,美國癌症協會於2025年1月發布的《2025年癌症事實與數據》預測,當年美國新增癌症病例將超過200萬例,凸顯了普及基因組分析的迫切性。傳染病的蔓延進一步加劇了這項需求。 2025年9月,美國疾病管制與預防中心(CDC)報告稱,2024年記錄性行為感染病例超過220萬例,凸顯了公共衛生領域診斷工作的巨大規模。
此外,熱感循環和qPCR儀器的技術進步透過最佳化工作流程效率和靈敏度,在市場成長中發揮關鍵作用。現代系統具有更高的溫度均勻性和更先進的演算法,簡化了高通量篩檢和複雜的熔解曲線分析。這些創新降低了准入門檻,使更多研究和診斷實驗室能夠採用這項技術進行基因分型和甲基化研究。該行業的強勁勢頭也體現在財務業績中。例如,賽默飛世爾科技公司在2025年1月公佈,第四季營收成長5%至114億美元,並將這項業績歸功於公司先進診斷和分析儀器的持續普及。
全球高解析度熔解曲線分析市場面臨的主要障礙是次世代定序(NGS) 成本的下降和日益普及。這種競爭方法具有更優異的多重檢測能力和靈敏度,能夠同時檢測罕見突變和多種基因變異,其性能標準往往是熔解曲線分析無法企及的。隨著臨床需求向全面的基因組分析發展,實驗室越來越傾向於選擇能夠更深入揭示複雜基因結構的定序平台,從而減少對熔解曲線分析在複雜診斷應用中的依賴。
這種轉變在腫瘤學和遺傳疾病管理領域尤其明顯,因為在這些領域,準確的突變分類至關重要。例如,美國癌症協會估計,到2024年,美國新增癌症病例數將首次超過200萬例。這些複雜疾病的增加推動了對定序所提供的全面基因組數據的需求,這也直接限制了熔解曲線分析技術在高階臨床診斷中的廣泛應用。
隨著 CRISPR/Cas9 技術的廣泛應用,高解析度熔解曲線分析 (HMA) 作為一種快速、經濟高效的篩檢方法,在進行高成本的定序之前,可用於檢測植物和細胞株中的突變並確認基因編輯,其應用日益普及。隨著研究活動的活性化,實驗室越來越依賴這項技術來有效檢驗引導 RNA 並確認基因突變。這種研發活動的活性化意義重大。 2025 年 2 月,CRISPR Therapeutics 在其「2024 會計年度第四季及全年」財務報告中揭露,公司擁有約 19 億美元的強勁現金儲備。這筆資金將用於支持公司廣泛的基因編輯治療產品線,並加速突變篩檢設備和試劑的使用。
同時,食品安全和農業領域正經歷顯著的市場成長,高解析度質譜(HRM)已成為種子品質檢測、植物鑑定和高通量作物基因型鑒定的關鍵技術。由於此方法無需複雜的PCR後處理即可快速區分近緣植物品種,並能辨識供應鏈中的詐欺行為,因此正日益取代傳統方法。主要服務供應商的財務表現也印證了這種檢測需求的規模。 Eurofins Scientific在2025年1月公佈的「2024會計年度」業績中,總收入創下69.5億歐元的紀錄,這主要得益於其北美食品和飼料檢測部門的持續有機成長。
The Global High-Resolution Melting Analysis Market is projected to expand from USD 2.59 Billion in 2025 to USD 4.54 Billion by 2031, reflecting a CAGR of 9.81%. High-Resolution Melting Analysis functions as a specialized technique for detecting genetic variations in nucleic acid sequences by observing fluorescence shifts in double-stranded DNA binding dyes during thermal denaturation. Market growth is primarily driven by the method's speed and cost-effectiveness compared to sequencing, rendering it ideal for extensive genotyping and methylation research. Additionally, the increasing burden of infectious diseases and genetic conditions fuels the need for such accessible diagnostic tools. As reported by MedTech Europe in 2024, the European medical technology sector was valued at approximately 170 billion Euros, with in vitro diagnostics leading the market, highlighting the strong industrial ecosystem supporting these analytical methods.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.59 Billion |
| Market Size 2031 | USD 4.54 Billion |
| CAGR 2026-2031 | 9.81% |
| Fastest Growing Segment | Reagents and Consumables |
| Largest Market | North America |
Conversely, the market encounters substantial hurdles due to the decreasing costs and broader availability of Next Generation Sequencing. This rival technology provides enhanced sensitivity and multiplexing abilities for identifying rare variants, often surpassing the resolution capabilities of melting analysis in intricate clinical scenarios. Consequently, laboratories that require exhaustive genomic profiling may prefer sequencing platforms over melting analysis, a trend that could constrain the latter's growth within advanced diagnostic environments.
Market Driver
The increasing prevalence of infectious diseases and genetic disorders acts as a major driver for the Global High-Resolution Melting Analysis Market, creating a demand for fast and affordable mutation scanning capabilities. As these health burdens increase, clinical laboratories are turning to melting analysis for the efficient identification of pathogens and single nucleotide polymorphisms, avoiding the complexity associated with sequencing. For example, the American Cancer Society's 'Cancer Facts & Figures 2025' from January 2025 projected over 2 million new cancer diagnoses in the United States for the year, emphasizing the urgent need for accessible genomic profiling. This demand is further intensified by the spread of communicable diseases; the Centers for Disease Control and Prevention reported in September 2025 that there were over 2.2 million recorded sexually transmitted infections in 2024, underscoring the vast diagnostic scale required in public health.
Furthermore, technological improvements in thermal cycling and qPCR instrumentation play a crucial role in market growth by optimizing workflow efficiency and sensitivity. Modern systems feature enhanced temperature uniformity and advanced algorithms that simplify high-throughput screening and the analysis of complex melt curves. These innovations lower entry barriers, enabling a wider array of research and diagnostic facilities to implement the technology for genotyping and methylation studies. The strength of this industry is reflected in financial results; for instance, Thermo Fisher Scientific reported in January 2025 that their fourth-quarter revenue rose by 5% to $11.40 billion, a performance attributed in part to the continued adoption of their sophisticated diagnostic and analytical instruments.
Market Challenge
A major obstacle for the Global High-Resolution Melting Analysis Market is the falling cost and growing accessibility of Next Generation Sequencing. This competing approach offers superior multiplexing and sensitivity, allowing for the concurrent detection of rare mutations and multiple genetic variants, achieving performance standards that melting analysis frequently fails to match. As clinical needs evolve toward comprehensive genomic profiling, laboratories often favor sequencing platforms that offer profound insights into complex genetic structures, thereby diminishing their dependence on melting analysis for high-complexity diagnostic applications.
This shift is especially evident in oncology and genetic disorder management, where precise variant classification is critical. For example, the American Cancer Society estimated that the number of new cancer cases in the United States in 2024 would exceed 2 million for the first time. The rising burden of such complex pathologies fuels the necessity for the exhaustive genomic data provided by sequencing, which directly restricts the broader adoption of melting analysis technologies within advanced clinical diagnostic settings.
Market Trends
The widespread adoption of CRISPR/Cas9 technology has established a trend wherein High-Resolution Melting is increasingly employed as a rapid, cost-efficient screening method to detect mutations and verify gene edits in plants and cell lines prior to utilizing costly sequencing. As research efforts intensify, laboratories depend on this technique to streamline the validation of guide RNA efficacy and confirm genetic alterations. This heightened development activity is significant; in February 2025, CRISPR Therapeutics reported a strong cash position of roughly $1.9 billion in their 'Fourth Quarter and Full Year 2024 Financial Results', capital which supports their extensive gene-edited therapy pipeline and drives the usage of mutation screening instruments and reagents.
Concurrently, the market is seeing substantial growth within the food safety and agricultural sectors, where HRM is essential for seed quality testing, botanical authentication, and high-throughput crop genotyping. This approach is superseding traditional methods because of its capacity to quickly differentiate closely related plant cultivars and identify supply chain adulteration without the need for intricate post-PCR processing. The magnitude of this testing demand is illustrated by the financial results of major service providers; Eurofins Scientific reported record total revenues of €6.95 billion in their January 2025 '2024 Full Year Results', a success largely driven by the continued organic expansion of their Food and Feed Testing division in North America.
Report Scope
In this report, the Global High-Resolution Melting Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global High-Resolution Melting Analysis Market.
Global High-Resolution Melting Analysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: